Six researchers at Fred Hutchinson Cancer Center have received nearly $3.5 million in grants from the Kuni Foundation, bringing the foundation’s support for Fred Hutch to more than $12 million since 2020.
The proposed projects will evaluate circulating tumor DNA, or ctDNA, as a biomarker for Merkel cell carcinoma, or MCC; develop a therapeutic antibody to eradicate metastatic breast cancer; develop an oncolytic measles virus to treat B-cell non-Hodgkin lymphoma, or B-NHL; test the safety and feasibility of a novel combination therapy for retroperitoneal liposarcoma; and use multiomics and artificial intelligence to design personalized meningioma therapy.
